CA2555939A1 - Traitement des anomalies de la premiere articulation metatarsophalangienne du pied - Google Patents
Traitement des anomalies de la premiere articulation metatarsophalangienne du pied Download PDFInfo
- Publication number
- CA2555939A1 CA2555939A1 CA002555939A CA2555939A CA2555939A1 CA 2555939 A1 CA2555939 A1 CA 2555939A1 CA 002555939 A CA002555939 A CA 002555939A CA 2555939 A CA2555939 A CA 2555939A CA 2555939 A1 CA2555939 A1 CA 2555939A1
- Authority
- CA
- Canada
- Prior art keywords
- toxin
- hallux
- muscle
- patient
- neuromuscular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000005856 abnormality Effects 0.000 title claims abstract description 19
- 210000000878 metatarsophalangeal joint Anatomy 0.000 title abstract description 23
- 231100000765 toxin Toxicity 0.000 claims abstract description 89
- 239000003053 toxin Substances 0.000 claims abstract description 88
- 108700012359 toxins Proteins 0.000 claims abstract description 88
- 210000003205 muscle Anatomy 0.000 claims abstract description 62
- 208000001963 Hallux Valgus Diseases 0.000 claims abstract description 23
- 230000002232 neuromuscular Effects 0.000 claims abstract description 22
- 208000008347 Hallux Limitus Diseases 0.000 claims abstract description 11
- 108030001720 Bontoxilysin Proteins 0.000 claims abstract description 10
- 229940053031 botulinum toxin Drugs 0.000 claims abstract description 10
- 208000009725 Hallux Varus Diseases 0.000 claims abstract description 9
- 206010061159 Foot deformity Diseases 0.000 claims abstract description 5
- 208000006327 Hallux Rigidus Diseases 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract 4
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims description 10
- 229940094657 botulinum toxin type a Drugs 0.000 claims description 9
- 230000008901 benefit Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 3
- 108010074523 rimabotulinumtoxinB Proteins 0.000 claims description 3
- 210000002683 foot Anatomy 0.000 abstract description 15
- 210000005036 nerve Anatomy 0.000 abstract description 4
- 230000002452 interceptive effect Effects 0.000 abstract description 3
- 241000124008 Mammalia Species 0.000 abstract 1
- 210000001255 hallux Anatomy 0.000 description 22
- 238000000034 method Methods 0.000 description 20
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 230000000638 stimulation Effects 0.000 description 13
- 210000001015 abdomen Anatomy 0.000 description 10
- 239000007927 intramuscular injection Substances 0.000 description 10
- 238000010255 intramuscular injection Methods 0.000 description 10
- 241001016288 Sesamoides Species 0.000 description 8
- 210000001872 metatarsal bone Anatomy 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 7
- 238000005259 measurement Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 231100000189 neurotoxic Toxicity 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 206010006585 Bunion Diseases 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 150000005829 chemical entities Chemical class 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000002887 neurotoxic effect Effects 0.000 description 3
- 239000002581 neurotoxin Substances 0.000 description 3
- 231100000618 neurotoxin Toxicity 0.000 description 3
- 101710138657 Neurotoxin Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical class 0.000 description 2
- 206010005159 blepharospasm Diseases 0.000 description 2
- 230000000744 blepharospasm Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000000453 second toe Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 241001112696 Clostridia Species 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000033952 Paralysis flaccid Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 108010069038 botulinum toxin type F Proteins 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 201000002866 cervical dystonia Diseases 0.000 description 1
- 238000012993 chemical processing Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940098753 dysport Drugs 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 238000002567 electromyography Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 208000028331 flaccid paralysis Diseases 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 229940112646 myobloc Drugs 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000002387 neurotoxicological effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 108010092231 staphylococcal alpha-toxin Proteins 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
- 229950010357 tetrodotoxin Drugs 0.000 description 1
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000000406 toxicity enhancer Substances 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54401704P | 2004-02-12 | 2004-02-12 | |
| US60/544,017 | 2004-02-12 | ||
| PCT/US2005/004599 WO2005079828A2 (fr) | 2004-02-12 | 2005-02-11 | Traitement des anomalies de la premiere articulation metatarsophalangienne du pied |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2555939A1 true CA2555939A1 (fr) | 2005-09-01 |
Family
ID=34885996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002555939A Abandoned CA2555939A1 (fr) | 2004-02-12 | 2005-02-11 | Traitement des anomalies de la premiere articulation metatarsophalangienne du pied |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1715888B1 (fr) |
| JP (1) | JP2007522240A (fr) |
| AT (1) | ATE368473T1 (fr) |
| AU (1) | AU2005215521A1 (fr) |
| CA (1) | CA2555939A1 (fr) |
| DE (1) | DE602005001854T2 (fr) |
| WO (1) | WO2005079828A2 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8870876B2 (en) | 2009-02-13 | 2014-10-28 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
| US8277459B2 (en) | 2009-09-25 | 2012-10-02 | Tarsus Medical Inc. | Methods and devices for treating a structural bone and joint deformity |
| US8652141B2 (en) | 2010-01-21 | 2014-02-18 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
| US8696719B2 (en) | 2010-06-03 | 2014-04-15 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
| BR112019019023A2 (pt) | 2017-03-13 | 2020-04-22 | Andrew Radovic Philip | toxina neuromuscular para uso no tratamento de uma anormalidade da primeira articulação metatarso-falangeana de um pé |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2332905T3 (es) * | 1993-12-28 | 2010-02-15 | Allergan, Inc. | Uso del componente neurotoxico de la toxina botulinica para el tratamiento de trastornos de musculos lisos. |
| WO2003101483A1 (fr) * | 2002-05-31 | 2003-12-11 | Solux Corporation | Preparation pharmaceutique de neurotoxine de botulinum, ses procedes de synthese et des methodes d'utilisation clinique |
-
2005
- 2005-02-11 JP JP2006553312A patent/JP2007522240A/ja active Pending
- 2005-02-11 AU AU2005215521A patent/AU2005215521A1/en not_active Abandoned
- 2005-02-11 EP EP05713491A patent/EP1715888B1/fr not_active Expired - Lifetime
- 2005-02-11 WO PCT/US2005/004599 patent/WO2005079828A2/fr not_active Ceased
- 2005-02-11 DE DE602005001854T patent/DE602005001854T2/de not_active Expired - Fee Related
- 2005-02-11 AT AT05713491T patent/ATE368473T1/de not_active IP Right Cessation
- 2005-02-11 CA CA002555939A patent/CA2555939A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1715888B1 (fr) | 2007-08-01 |
| EP1715888A2 (fr) | 2006-11-02 |
| AU2005215521A1 (en) | 2005-09-01 |
| WO2005079828A3 (fr) | 2005-12-22 |
| DE602005001854T2 (de) | 2008-04-17 |
| DE602005001854D1 (de) | 2007-09-13 |
| WO2005079828A2 (fr) | 2005-09-01 |
| ATE368473T1 (de) | 2007-08-15 |
| JP2007522240A (ja) | 2007-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080008777A1 (en) | Methods of treating a bunion | |
| US20080206224A1 (en) | Muscle contraction treatment utilizing botulinum toxin | |
| US7854929B2 (en) | Method for treating lateral epicondylitis using collagenase | |
| JP4381477B2 (ja) | 筋膜疼痛症候群の治療方法 | |
| US7384918B2 (en) | Botulinum toxin for treating muscle contracture | |
| WO2008131941A1 (fr) | Traitement de troubles de la motricité par une utilisation combinée d'une toxine botulinique et d'une stimulation musculaire | |
| US20080181917A1 (en) | Methods for therapeutic treatment of carpal tunnel syndrome | |
| US7276244B2 (en) | Methods of treating abnormalities of the first metatarsophalangeal joint of the foot | |
| CN101107006B (zh) | 治疗黏连性关节囊炎的方法 | |
| EP1715888B1 (fr) | Traitement des anomalies de la premiere articulation metatarsophalangienne du pied | |
| US20070128226A1 (en) | Methods of treating pain associated with abnormalities of the first metatarsophalangeal joint of the foot | |
| RU2734159C1 (ru) | Фармацевтическая композиция для лечения болевого синдрома в стопе, включающая ботулинический токсин и гиалуроновую кислоту, и способ лечения болевого синдрома в стопе с ее использованием | |
| US10869914B2 (en) | Methods of treating abnormalities of the first metatarsophalangeal joint of the foot | |
| US20180333472A1 (en) | Treatment of plantar fasciitis | |
| RU2854723C1 (ru) | Лечение послеоперационной хирургической боли | |
| US10561715B2 (en) | Plantar heel pain syndrome treatment | |
| Safarpour et al. | 33 with Botulinum Neurotoxins | |
| US10071143B1 (en) | Methods for non-surgical treatment of carpal tunnel syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |